Biogen (BIIB)
(Delayed Data from NSDQ)
$218.20 USD
+0.90 (0.41%)
Updated Aug 5, 2022 04:00 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Price, Consensus and EPS Surprise
BIIB 218.20 +0.90(0.41%)
Will BIIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
Other News for BIIB
EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
Robert W. Baird Reaffirms Their Hold Rating on Biogen (BIIB)
SVB Securities Thinks Biogen`s Stock is Going to Recover
September 9th Options Now Available For Biogen (BIIB)
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus